TELOMERES AND TELOMERASE ACTIVITY IN CHRONIC MYELOID LEUKEMIA (REVIEW)
https://doi.org/10.15372/SSMJ20190114
Abstract
A review of literature data on the change in telomere length and telomerase activity at various stages of chronic myeloid leukemia (CML) has been performed. It has been shown that telomere length is reduced faster in the BCR-ABL-positive cells due to their rapid division. It has been reported that telomere length correlates with the remaining time until the disease progresses. Thus, the accelerated reduction of telomeres can be regarded as a sign of a poor prognosis of the disease. It was found that the rate of contraction of telomere length during the progression of the disease was 10–20 times higher than that observed in normal granulocytes and blast cells (tumor samples underwent at least 30–60 additional divisions from the base length of Ph-telomeres). More than 50 % of patients with CML (blast crisis) had a 50-fold increase in telomerase activity. The length of telomeres gradually increased when the cytogenetic response was achieved in the treatment of CML by imatinib or interferon-alpha. Inhibition of telomerase is a new possible therapeutic approach to the treatment of myeloproliferative and solid tumors. Various therapeutic approaches to the inhibition of telomerase have been developed.
About the Authors
A. S. Lyamkina
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Anna Sergeevna LYAMKINA – candidate of medical sciences, docent at the department of therapy, hematology and transfusiology
630091, Novosibirsk, Krasny av., 52
T. I. Pospelova
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Tatyana Ivanovna POSPELOVA – doctor of medical sciences, professor, vice-rector for research, head department of therapy, hematology and transfusiology
630091, Novosibirsk, Krasny av., 52
References
1. Bakalova R., Ohba H., Zhelev Z., Ishikawa M., Shinohara Y., Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase – a potential reason for resistance to Glivec in chronic myelogenous leukaemia // Biochem. Pharmacol. 2003. 66. (10). 1879–1884.
2. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA // Cell. 1997. 91. (1). 25–34.
3. Bogdanov A.A. Telomeres and telomerase // Sorosovskiy obrazovatel'nyy zhurnal = Soros Educational Journal. 1998. (12). 12-18. [In Russian].
4. Bollmann, F.M. Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer // Cancer Treat. Rev. 2007. 33. 704–709.
5. Boultwood J., Fidler C., Shepherd P., Watkins F., Snowball J., Haynes S., Kusec R., Gaiger A., Littlewood T.J., Peniket A.J., Wainscoat J.S. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia // Am. J. Hematol. 1999. 61(1). 5–9.
6. Broccoli D., Young J.W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells // Proc. Natl. Acad. Sci. USA. 1995. 92. (20). 9082–9086.
7. Brummendorf T.H., Ersoz I., Hartmann U., Bartolovic K., Balabanov S., Wahl A., Paschka P., Kreil S., Lahaye T., Berger U., Gschaidmeier H., Bokemeyer C., Hehlmann R., Dietz K., Lansdorp P.M., Kanz L., Hochhaus A. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia // Blood. 2003. 101. (1). 375–376.
8. Brummendorf T.H., Holyoake T.L., Rufer N., Barnett M.J., Schulzer M., Eaves C.J., Eaves A.C., Lansdorp P.M. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry // Blood. 2000. 95. (6). 1883–1890.
9. Campbell L.J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., Littlewood T.J., Wainscoat J.S., Boultwood J. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia // Leukemia. 2006. 20. (4). 671–679.
10. Cerone M.A., Londono-Vallejo J.A., Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells // Mol. Cancer Ther. 2006. 5. (7). 1669–1675.
11. Collins K. The biogenesis and regulation of telomerase holoenzymes // Nat. Rev. Mol. Cell. Biol. 2006. 7. 484–494.
12. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., Niestroj C., Daiber C., Enenkel B., Guilliard B., Lauritsch I., Muller E., Pascolo E., Sauter G., Pantic M., Martens U.M., Wenz C., Lingner J., Kraut N., Rettig W.J., Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation // EMBO J. 2001. 20. (24). 6958–6968.
13. Deng Y., Chan S.S., Chang S. Telomere dysfunction and tumour suppression: the senescence connection // Nat. Rev. Cancer. 2008. 8. (6). 450–458.
14. Drummond M., Lennard A., Brummendorf T., Holyoake T. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia // Leuk. Lymphoma. 2004. 45. (9). 1775–1781.
15. Durig J., Rosenthal S., Elmaagacli A., Heyworth C., Halfmeyer K., Kasper C., Novotny J., Duhrsen U. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells // Leukemia. 2000. 14(9). 1652-1660.
16. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture // Cancer Res. 2000. 60. (3). 610–617.
17. Fialkow P.J., Jacobson R.J., Papayannoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage // Am. J. Med. 1997. 63. 125-130.
18. Gordon M.Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment // Brit. J. Haematol. 1996. 95. 10-20
19. Greider C.W., Blackburn E.H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity // Cell. 1987. 51. 887–898.
20. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells // Nat. Med. 1999. 5. (10). 1164–1170.
21. Harley C.B. Telomerase and cancer therapeutics // Nat. Rev. Cancer. 2008. 8. (3). 167–179.
22. Hartmann U., Balabanov S., Ziegler P., Fellenberg J., van der Kuip H., Duyster J., Lipp H.P., Bokemeyer C., Kanz L., Brummendorf T.H. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib // Exp. Hematol. 2005. 33. (5). 542–549.
23. Hsu M., Yu E.Y., Singh S.M., Lue N.F. Mutual dependence of Candida albicans Est1p and Est3p in telomerase assembly and activation // Eukaryot. Cell. 2007. 6. (8). 1330–1338.
24. Iwama H., Ohyashiki K., Ohyashiki J.H., Hayashi S., Kawakubo K., Shay J.W., Toyama K. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia // Cancer. 1997. 79. (8). 1552–1560.
25. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells // FEBS Lett. 2004. 564. 9–13.
26. Kantarjian H.M., Talpaz M., O'Brien S., Smith T.L., Giles F.J., Faderl S., Thomas D.A., Garcia-Manero G., Issa J.P., Andreeff M., Kornblau S.M., Koller C., Beran M., Keating M., Rios M.B., Shan J., Resta D., Capdeville R., Hayes K., Albitar M., Freireich E.J., Cortes J.E. Imatinib mesylate for Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results // Clin. Cancer Res. 2002. 8. 2177-2187.
27. Kelleher C., Teixeira M.T., Forstemann K., Lingner J. Telomerase: biochemical considerations for enzyme and substrate // Trends Biochem. Sci. 2002. 27. 572–579.
28. Kharbanda S., Kumar V., Dhar S., Pandey P., Chen C., Majumder P., Yuan Z.M., Whang Y., Strauss W., Pandita T.K., Weaver D., Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase // Curr. Biol. 2000. 10. (10). 568–575.
29. Kloetzer W.S., Kurzrock R., Smith L., Talpaz M., Spiller M., Gutterman J., Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K-562 has associated tyrosine protein kinase activity // Virology. 1985. 140. 230-238.
30. Kurzrock R., Kantarjian H.M., Druker B.J., Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics // Ann. Intern. Med. 2003. 138. (10). 819-830.
31. Louis E.J., Vershinin A.V. Chromosome ends: different sequences may provide conserved functions // Bioessays. 2005. 27. 685-697
32. Lugo T.G., Pendergast A.M., Muller A.J. Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products // Science. 1990. 247. 1079-1082.
33. McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins // Mol. Cell. Biol. 1992. 11. 1553-1565.
34. Muller H.J. Further studies on the nature and causes of gene mutations // Proc. Sixth Int. Congr. Genet. 1932. 1. 213-255.
35. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia // Oncogene. 2002. 21. (4). 680–687.
36. Ohyashiki K., Iwama H., Tauchi T., Shimamoto T., Hayashi S., Ando K., Kawakubo K., Ohyashiki J.H. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia // Leuk. Lymphoma. 2000. 40. (1–2). 49–56.
37. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression // Leukemia. 1997. 11. (2). 190–194.
38. Osterhage J.L., Talley J.M., Friedman K.L. Proteasome-dependent degradation of Est1p regulates the cell cycle-restricted assembly of telomerase in Saccharomyces cerevisiae // Nat. Struct. Mol. Biol. 2006. 13. 720–728.
39. Peled A., Hardan I., Trakhtenbrot L., Gur E., Magid M., Darash-Yahana M., Cohen N., Grabovsky V., Franitza S., Kollet O., Lider O., Alon R., Rechavi G., Lapidot T. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1 // Stem cells. 2002. 20. (3). 259-266.
40. Roth A., Vercauteren S., Sutherland H.J., Lansdorp P.M. Telomerase is limiting the growth of acute myeloid leukemia cells // Leukemia. 2003. 17. (12). 2410–2417.
41. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia giemsa starting // Nature. 1973. 243. 290-303.
42. Shcherbakova D.M., Zvereva M.E., Shpanchenko O.V., Dontsova O.A. Telomerase: the structure and properties of the enzyme, and peculiarities of yeast telomerase. Mol. Biol. (Mosc.). 2006. 40. (4). 514–527.
43. Smith K.M., Yacobi R., Va Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain // Mol. Cell. 2003. 12. 27-37.
44. Steelman L.S., Pohnert S.C. Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in cell cycle progression and leukemogenesis // Leukemia. 2004. 18. (2). 189-218.
45. Van Etten R.A. Cycling, stressed-out and nervous of c-abl // Trend Cell. Biol. 1999. 9. 179-186.
46. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age // Proc. Natl. Acad. Sci. USA. 1994. 91. (21). 9857–9860.
47. Ward R.J, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment // Mol. Pharmacol. 2005. 68. (3). 779–786.
48. Zvereva M.E., Shcherbakova D.M., Dontsova O.A. Telomerase: structure, functions, and activity regulation. Biochemistry (Mosc.). 2010. 75. (13). 1563-1583.
Review
Views:
307
Email this article 